Hype Stories
Is now the time to sell Arrowmark Financial (USA Stocks:BANX)?
![]() | a day ago at Macroaxis By Raphi Shpitalnik |
The asset utilization ratio is a metric that indicates the revenue generated for every dollar of assets reported by a company. Arrowmark Financial Corp has an asset utilization ratio of 3.77 percent, which means that the company earns $0.0377 for each dollar of assets. An increasing asset utilization ratio suggests that Arrowmark Financial Corp is becoming more efficient in using its assets for day-to-day operations. Continue Reading...
- BANX Arrowmark Financial Corp
- Latest Will current Arrowmark Financial debt levels change in two-three weeks
- BANX 17.01 -0.12
- Low 17.0
- High 17.25
- Volume 15.8 K
- Alpha 0.0881
- Beta 0.45
- Return On Equity 0.0955
- Return On Asset 0.0598
- Profit Margin 0.56 %
- Operating Margin 0.77 %
- Current Valuation 170.53 M
- Shares Outstanding 7.11 M
- Shares Owned By Insiders 0.08 %
- Shares Owned By Institutions 25.72 %
- Number Of Shares Shorted 10.07 K
- Price To Earning 14.79 X
- Price To Book 0.80 X
- Price To Sales 4.82 X
- Revenue 7.86 M
- Gross Profit 21.53 M
- EBITDA 7.7 M
- Net Income 5.37 M
- Cash And Equivalents 149.73 K
- Cash Per Share 0.02 X
- Total Debt 55.6 M
- Debt To Equity 0.35 %
- Current Ratio 3.11 X
- Book Value Per Share 21.29 X
- Cash Flow From Operations 15.84 M
- Short Ratio 0.58 X
- Earnings Per Share 2.01 X
- Target Price 22.0
- Beta 0.5
- Market Capitalization 122.19 M
- Total Asset 208.5 M
- Retained Earnings (8.83 M)
- Z Score 1.42
- Annual Yield 0.11 %
- Five Year Return 7.42 %
- Net Asset 208.5 M
- Last Dividend Paid 1.56
Macroaxis uses a strict editorial review process to publish stories and blog posts. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Gabriel Shpitalnik
We offer trading recommendations to align with the current expert consensus on Assure Holdings Corp. Our sophisticated recommendation engine employs a multi-dimensional algorithm that evaluates the company's growth potential by analyzing all available technical and fundamental data.
Major Takeaways
For those investors looking to tap into the burgeoning medical care facilities industry, Assure Holdings Corp (IONM) presents a tantalizing opportunity. With a Price Percent Change of an impressive 29.63%, the company's stock has demonstrated a robust growth trajectory that can't be ignored.few days ago at Macroaxis By Aina Ster | ![]() |
In the world of investing, opportunity often comes dressed in the garb of misfortune. As the broader market rallies, Chindata Group Holdings, a prominent player in the technology sector, seems to have missed the memo, with its stock price lagging behind the euphoria. This divergence has left investors pondering whether the current situation presents a strategic buying opportunity.
few days ago at Macroaxis By Aina Ster | ![]() |
Every cloud has a silver lining, and in the case of Arrowmark Financial Corp (NASDAQ: BANX), that silver lining may be its undervalued status. Despite defying the market uptrend, the financial services company presents a potentially lucrative investment opportunity. With a valuation market value of 17.26, it's significantly undervalued compared to its valuation hype value of 17.26.
over a week ago at Macroaxis By Vlad Skutelnik | ![]() |
The proof of the pudding is in the eating, and for Four Seasons Education, a company listed on the NYSE and operating in the Education & Training Services industry, the taste might be a bit sour for private investors. As we approach December, there is a growing buzz around a potential sell-off of the company's stock. With a valuation hype value of 9.49, significantly higher than its valuation real value of 7.76, the stock appears overpriced.
over two weeks ago at Macroaxis By Gabriel Shpitalnik | ![]() |
Turnstone Biologics Corp (USA Stocks: TSBX) has been making waves in the biotechnology industry, with a recent price percent change of 5.66% and a potential upside of 24.47%. The stock's high price reached $3.6, with a low of $3.18, indicating a strong performance in the market. Despite a Jensen Alpha of -0.43, indicating a loss, the company's mean deviation of 9.66 and variance of 243.13 suggest a high level of volatility, which could be a boon for risk-tolerant investors looking to maximize returns.
over two weeks ago at Macroaxis By Nico Santiago | ![]() |
As we approach the end of the fiscal year, ChargePoint Holdings, a notable player in the Specialty Retail sector, specifically within the Electrical Equipment category, is generating significant buzz among investors. The question on everyone's mind is: Can we expect a December rally for this Consumer Cyclical industry stock? As of now, the stock's Valuation Market Value stands at $2.71 billion, while its Valuation Real Value is higher at $4.52 billion. This discrepancy indicates a potential undervaluation, hinting at a promising investment opportunity.
over two weeks ago at Macroaxis By Gabriel Shpitalnik | ![]() |
In the world of investing, fortune often favors the bold. Orchard Therapeutics PLC (NASDAQ: ORTX), a key player in the Biotechnology industry, seems to be capturing increased investor confidence. The company, which has its fiscal year end in December, has been the subject of considerable hype, with a valuation hype value of 16.59.
over two weeks ago at Macroaxis By Vlad Skutelnik | ![]() |
Every cloud has a silver lining, and for investors, that silver lining could be Metals Acquisition Limited. Despite the company's recent financial loss, there's a strong consensus among analysts that the stock is a 'Strong Buy'. With a real valuation of $11.29, which is slightly higher than the market valuation of $10.4, there's a potential upside.
over three weeks ago at Macroaxis By Raphi Shpitalnik | ![]() |
The market is a voting machine in the short term, but a weighing machine in the long term. This well-known investment aphorism seems to be playing out for Miromatrix Medical (USA Stocks: MIRO), a prominent player in the biotechnology industry. The company's stock has been the subject of considerable hype recently, with a notable increase in insider confidence.
over a month ago at Macroaxis By Gabriel Shpitalnik | ![]() |